Clinical Trial Results: First-in-Human Study of TAK-280 in Participants With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

First-in-human study of TAK-280 in adults with unresectable locally advanced or metastatic cancer (Phase 1/2) is terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Unresectable Locally Advanced or Metastatic Cancer

Drugs mentioned

• TAK-280 (TAK-280)

Snippet

Sponsor: Takeda | Conditions: Unresectable Locally Advanced or Metastatic Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-07-07